Breaking News Instant updates and real-time market news.

ACAD

Acadia

$24.04

-0.31 (-1.27%)

09:12
04/25/19
04/25
09:12
04/25/19
09:12

Acadia initiates Phase 3 CLARITY program with pimavanserin

ACADIA Pharmaceuticals announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months. These studies will evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with major depressive disorder who have an inadequate response to standard antidepressant therapy with either a selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor. Pimavanserin is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors, which may play a role in depression.

  • 01

    May

  • 04

    May

ACAD Acadia
$24.04

-0.31 (-1.27%)

11/13/18
LEER
11/13/18
INITIATION
Target $21
LEER
Market Perform
Acadia initiated with a Market Perform at Leerink
Leerink analyst Marc Goodman started Acadia with a Market Perform and $21 price target as he initiates Neuroscience space with a Positive View. The analyst believes the Neuroscience sector is experiencing a "renaissance" as multiple new agents and mechanisms are coming up the pipeline across major therapeutic areas, the number of clinical studies is growing nicely, and the FDA is friendly to innovation in this space, companies are getting smarter about speed-to-market strategies and selecting niche sub-populations to focus on for initial product approvals, payer pushback on usage is much lower than in other categories, and physicians are enthusiastic about new agents. Regarding Acadia, Goodman believes Nuplazid will rebound following the negative publicity regarding its safety profile based on his proprietary MEDACorp physician survey work, but consensus now assumes a rebound.
12/10/18
ADAM
12/10/18
INITIATION
Target $23
ADAM
Hold
Acadia initiated with a Hold at Canaccord
Canaccord analyst Sumant Kulkarni initiated Acadia Pharmaceuticals with a Hold rating and $23 price target. In a research note to investors, Kulkarni says that while he believes Acadia is a core holding for investors seeking exposure to central nervous system, or CNS, companies with commercial assets, he believes the risk/reward on the stock is balanced ahead of potential issuance of the company's initial 2019 outlook for Nuplazid in Parkinson's Disease psychosis, or PDP, and views his sales estimate for Nuplazid as "reasonable," though he admits he has low visibility heading into the event.
02/27/19
ADAM
02/27/19
NO CHANGE
Target $27
ADAM
Hold
Canaccord says Acadia shares 'getting interesting,' raises price target to $27
Canaccord analyst Sumant Kulkarni said Acadia reported decent Q4 results, with Nuplazid sales coming in in-line with expectations. The outlook was solid, suggesting the media issues the drug faced are behind it, which is encouraging, said Kulkarni. With that out of the way, the analyst believes the stock is getting more interesting heading into data readouts for the company's dementia and schizophrenia drugs. Kulkarni maintained his Hold rating and raised his price target to $27 from $23 on Acadia shares.
02/27/19
PIPR
02/27/19
NO CHANGE
Target $30
PIPR
Overweight
Acadia price target raised to $30 from $25 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Acadia Pharmaceuticals to $30 following the company's Q4 results. The analyst expects Nuplazid' "modest" revenue growth to continue as safety concerns "slowly subside." She also anticipates a beneficial impact to 2019 sales from the ongoing direct-to-consumer campaign. As such, the company's fiscal 2019 guidance of $275M-$300M "appears in line and readily achievable," Brill tells investors in a post-earnings research note. With Acadia beginning two Phase 3 major depressive disorder trials in the first half of 2019, the analyst expects the shares to start reflecting value for the indication as the program continues to advance. She introduced probability-adjusted numbers at a 25% chance of success into her model and keeps an Overweight rating on Acadia.

TODAY'S FREE FLY STORIES

STIM

Neuronetics

$11.41

-0.11 (-0.95%)

05:21
06/18/19
06/18
05:21
06/18/19
05:21
Recommendations
Neuronetics analyst commentary  »

Neuronetics reiterated as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LGF.B

Lionsgate

$11.30

-0.04 (-0.35%)

, LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

05:17
06/18/19
06/18
05:17
06/18/19
05:17
Recommendations
Lionsgate, Use LGF.A, LGF.B analyst commentary  »

Lionsgate price target…

LGF.B

Lionsgate

$11.30

-0.04 (-0.35%)

LGF

Use LGF.A, LGF.B

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRAY

ViewRay

$8.96

0.215 (2.46%)

05:14
06/18/19
06/18
05:14
06/18/19
05:14
Initiation
ViewRay initiated  »

ViewRay initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLAKY

Lufthansa

$0.00

(0.00%)

05:12
06/18/19
06/18
05:12
06/18/19
05:12
Downgrade
Lufthansa rating change  »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRZF

Evraz

$0.00

(0.00%)

05:11
06/18/19
06/18
05:11
06/18/19
05:11
Downgrade
Evraz rating change  »

Evraz downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EVRZF

Evraz

$0.00

(0.00%)

05:10
06/18/19
06/18
05:10
06/18/19
05:10
Downgrade
Evraz rating change  »

Evraz downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

USM

U.S. Cellular

$44.15

0.375 (0.86%)

05:09
06/18/19
06/18
05:09
06/18/19
05:09
Upgrade
U.S. Cellular rating change  »

U.S. Cellular upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$29.21

-0.11 (-0.38%)

05:08
06/18/19
06/18
05:08
06/18/19
05:08
Upgrade
Telephone and Data rating change  »

Telephone and Data…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESS

Essex Property Trust

$302.21

3.03 (1.01%)

05:07
06/18/19
06/18
05:07
06/18/19
05:07
Downgrade
Essex Property Trust rating change  »

Essex Property Trust…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 10

    Jul

  • 11

    Jul

CFPZF

Canfor

$0.00

(0.00%)

05:06
06/18/19
06/18
05:06
06/18/19
05:06
Upgrade
Canfor rating change  »

Canfor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WFTBF

West Fraser Timber

$0.00

(0.00%)

05:05
06/18/19
06/18
05:05
06/18/19
05:05
Upgrade
West Fraser Timber rating change  »

West Fraser Timber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RFP

Resolute Forest

$6.12

0.015 (0.25%)

05:05
06/18/19
06/18
05:05
06/18/19
05:05
Upgrade
Resolute Forest rating change  »

Resolute Forest upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DLAKY

Lufthansa

$0.00

(0.00%)

05:03
06/18/19
06/18
05:03
06/18/19
05:03
Downgrade
Lufthansa rating change  »

Lufthansa downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACCYY

Accor

$0.00

(0.00%)

05:02
06/18/19
06/18
05:02
06/18/19
05:02
Upgrade
Accor rating change  »

Accor upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNY

Sanofi

$42.65

0.19 (0.45%)

05:01
06/18/19
06/18
05:01
06/18/19
05:01
Downgrade
Sanofi rating change  »

Sanofi downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

  • 16

    Sep

AXELF

Axel Springer

$0.00

(0.00%)

04:59
06/18/19
06/18
04:59
06/18/19
04:59
Downgrade
Axel Springer rating change  »

Axel Springer downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OTSKY

Otsuka

$0.00

(0.00%)

04:58
06/18/19
06/18
04:58
06/18/19
04:58
Downgrade
Otsuka rating change  »

Otsuka downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LEN

Lennar

$53.01

-0.54 (-1.01%)

04:56
06/18/19
06/18
04:56
06/18/19
04:56
Downgrade
Lennar rating change  »

Lennar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jun

KBH

KB Home

$26.21

-0.24 (-0.91%)

04:56
06/18/19
06/18
04:56
06/18/19
04:56
Downgrade
KB Home rating change  »

KB Home downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jun

VZ

Verizon

$57.63

-0.65 (-1.12%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
Verizon to host sell side analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 20

    Jun

  • 26

    Jun

  • 27

    Jun

  • 09

    Jul

  • 01

    Aug

CVS

CVS Health

$54.52

0.34 (0.63%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
CVS Health participates in a conference call with JPMorgan »

Healthcare Technology…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 18

    Jun

ARWR

Arrowhead

$26.43

0.62 (2.40%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
Arrowhead management to meet with Piper Jaffray »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

HRB

H&R Block

$28.34

-0.35 (-1.22%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
H&R Block management to meet with Northcoast »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 16

    Jul

GIII

G-III Apparel

$25.67

-0.03 (-0.12%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
G-III Apparel management to meet with KeyBanc »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

  • 09

    Jul

DEI

Douglas Emmett

$41.86

0.595 (1.44%)

04:55
06/18/19
06/18
04:55
06/18/19
04:55
Conference/Events
Douglas Emmett management to meet with KeyBanc »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Jun

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.